Yaohong Pharmaceuticals (688176.SH): has repurchased 1.4651% of the shares accumulated.
Galaxy Today, Yuhong Medicine (688176.SH) announced that as of September 30, 2024, the company has repurchased a total of 8,351,322 shares, accounting for 1.4651% of the total share capital. The highest purchase price was RMB 6.73 per share, the lowest price was RMB 4.99 per share, and the total amount paid was RMB 47.787 million (excluding stamp duty, transaction commission, and other transaction costs).
Yatai Pharmaceuticals (688176.SH): Granted 8.3201 million restricted stocks to 68 incentive recipients.
Golden stock September 27th, Aohong Pharmaceutical (688176.SH) announced that the company has set September 27, 2024 as the grant date, and will grant 8.3201 million restricted stocks to 68 incentive targets at a grant price of 3.06 yuan per share.
Jiangsu Yahong Meditech Finishes Phase 2 Trial for Muscle-Invasive Bladder Cancer Pre-Treatment Combo
Yahong Medical (688176.SH): The Phase II clinical trial of APL-1202 oral combination with Toripalimab as neoadjuvant treatment for muscle-invasive bladder cancer has been completed and has shown positive efficacy signals.
On September 25, Gelonghui announced that Yahong Medicine (688176.SH) disclosed the completion of Phase II clinical trial of APL-1202 oral combination with Toripalimab as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) in stage I/II with positive therapeutic signals. The main objective of this Phase II clinical trial is to evaluate the safety and efficacy of APL-1202 in combination with Toripalimab compared to Toripalimab monotherapy as neoadjuvant therapy in MIBC subjects. The study population consists of subjects who are newly diagnosed with MIBC and planning to undergo radical cystectomy, intolerant or refusing to receive
Express News | Yuhong Medicine: APL-1202 combined with Trastuzumab achieves positive therapeutic signal in the treatment of MIBC.
Yahong Pharmaceuticals (688176): APL-1702 data readout
Event: On September 18, the company announced that the prospective, randomized, double-blind, placebo-controlled international multi-center Phase III clinical trial results for product APL-1702 for the treatment of high-grade squamous intraepithelial lesions (HSIL) of the cervix were selected.
Yahong Meditech Says APL1702 Drug's Trial Shows Positive Results; Shares Down 3%
Express News | Yahong Medicine: The results of the international multi-center Phase III clinical trial of product APL-1702 were selected for the 2024 International Photodynamic Therapy and Photodiagnostics Conference.
Yahong Pharmaceuticals-U(688176): Continuing to advance the progress of the pipeline
Event: Recently, the company released the 2024 interim report. In the first half of 2024, the company achieved a revenue of 80.493 million yuan, and a net income attributable to shareholders of the listed company of -0.184 billion yuan. APL-1702 submitted.
Yahong Medicine (688176.SH) released its semi-annual performance, with a net loss of 0.184 billion yuan.
Yahong Pharmaceutical (688176.SH) disclosed its 2024 interim report. During the reporting period, the company achieved revenue of 8,049...
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Express News | Yahong Medicine: Proposes to launch a restricted stock incentive plan of 8.3201 million shares.
Yahong Medicine (688176.SH): plans to launch a restricted stock incentive plan for 8.3201 million shares.
Gelonghui announced on August 28th that YAHong Pharmaceuticals (688176.SH) has released a restricted stock incentive plan for 2024. The plan plans to grant 8.3201 million restricted stocks to the incentive recipients, accounting for approximately 1.46% of the total shares of the company's capital, which was 570 million shares at the time of the announcement of the incentive plan draft. The grant is a one-time grant with no reserved portions.
Yuhong Pharmaceutical (688176.SH): The revenue in Q2 of 2024 increased by 130.98% month-on-month, and the core products are steadily progressing to market.
GLEH August 28th | Yahong Medicine (688176.SH) released its 2024 interim report, achieving a revenue of 80.4934 million yuan in the first half of 2024, of which 56.1739 million yuan was realized in the second quarter, a 130.98% increase from the previous quarter. In addition, the company is actively promoting the launch of two core products. The new drug application for APL-1702 has been accepted, and the company is actively advancing its listing review and approval work. At present, the progress is smooth and is expected to become the world's first non-surgical treatment for high-grade squamous intraepithelial lesions of the cervix. APL-1706 has successfully passed the national drug
YaHong Medical (688176.SH): has repurchased 1.3608% of the shares.
On August 1st, Gelonhui announced that as of July 31, 2024, the company had cumulatively repurchased 7,756,291 shares, accounting for 1.3608% of the total share capital, with a maximum repurchase price of RMB 6.73 per share, and a minimum price of RMB 5.02 per share. The total amount paid was RMB 44.79 million (excluding stamp duty, transaction commission and other trading expenses).
Yahong Medicine (688176.SH): has repurchased 1.0685% of the shares cumulatively.
On July 3rd, Gelonhui reported that Yahong Medicine (688176.SH) has cumulatively repurchased 6,090,403 shares through centralized bidding trading as of July 3, 2024, accounting for 1.0685% of the total equity of the company. Compared with the previous disclosure, the proportion has increased by 0.4419%. The highest price for repurchase transactions was RMB 6.73 per share, the lowest price was RMB 5.08 per share, and the total amount paid was RMB 36,196,800 (excluding stamp duty, transaction commissions, and other transaction costs).
Yahong Pharmacy (688176.SH): the actual controller and financial person in charge have completed the shareholding, costing 4 million yuan.
Yahong Pharmaceutical (688176.SH) announced that as of July 2, 2024, the company's controlling shareholder and actual controller...
Yahong Meditech to Trial Drug Against Amoebae Infection
Yahong Pharmaceutical (688176.SH): APL-1202 clinical trial application has been approved by the National Medical Products Administration.
On June 24th, Gelunhui reported that Jiangsu Yahong Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "company") has received the drug clinical trial approval notice issued by the National Medical Products Administration (NMPA) for APL-1202, which is used to treat Free-living Amoebae (FLA) infection. This study is an evaluation of the use of hydroxychloroquine tablets (APL-1202) to treat Free-living Amoebae.
No Data
No Data